Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "safety"

1075 News Found

CuraTeQ Biologics completes Phase 1 Pharmacokinetics study of biosimilar Denosumab
News | April 09, 2025

CuraTeQ Biologics completes Phase 1 Pharmacokinetics study of biosimilar Denosumab

This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets


Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
News | April 08, 2025

Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses

Asahi Kasei Life Science covers a broad range of bioprocess products and services


Lyka Labs secures Indian patent for Pregabalin Gel 8%
News | April 08, 2025

Lyka Labs secures Indian patent for Pregabalin Gel 8%

Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain


Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms
News | April 07, 2025

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs


Asahi Kasei Life Science begins operation
News | April 03, 2025

Asahi Kasei Life Science begins operation

Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture


Merck seeks FDA approval for subcutaneous pembrolizumab
Drug Approval | March 29, 2025

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy


Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
News | March 29, 2025

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)


European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
Drug Approval | March 27, 2025

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults


BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK
Drug Approval | March 21, 2025

BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions


USFDA grants Priority Review for new indication of finerenone for patients with common heart failure
Drug Approval | March 20, 2025

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure